Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL056 vs alendronate in postmenopausal osteoporosis at high fracture risk
CTR20212418Phase 3Completed
- Sponsor
- Chengdu Jinkai Biotechnology
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of Xinfutai in osteoporosis, sponsored by Chengdu Jinkai Biotechnology. Started Oct 2021; status: completed.
02
Drugs
Xinfutai
03
Conditions
osteoporosis
Beyond the preview
Go deeper on CTR20212418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212418.